{"study_desc":{"study_info":{"nation":[{"name":"Ghana","abbreviation":"GH"}],"notes":"Abstract\nBackground: The Global Programme for the Elimination of Lymphatic Filariasis (GPELF) has been in operation since\nthe year 2000, with the aim of eliminating the disease by the year 2020, following five to six rounds of effective\nannual mass drug administration (MDA). The treatment regimen is ivermectin (IVM) in combination with\ndiethylcarbamazine (DEC) or albendazole (ALB). In Ghana, MDA has been undertaken since 2001. While the disease\nhas been eliminated in many areas, transmission has persisted in some implementation units that had experienced\n15 or more rounds of MDA. Thus, new intervention strategies could eliminate residual infection in areas of\npersistent transmission and speed up the lymphatic filariasis (LF)-elimination process. This study, therefore, seeks\nto test the hypothesis that biannual treatment of LF-endemic communities will accelerate the interruption of LF in\nareas of persistent transmission.\nMethods: A cluster randomised trial will be implemented in LF-endemic communities in Ghana. The interventions\nwill be yearly or twice-yearly MDA delivered to entire endemic communities. Allocation to study group will be by\nclusters identified using the prevalence of LF. Clusters will be randomised to one of two groups: receiving either (1)\nannual treatment with IVM+ ALB or (2) annual MDA with IVM+ ALB, followed by an additional MDA 6 months later.\nThe primary outcome measure is the prevalence of LF infection, assessed by four cross-sectional surveys.\nEntomological assessments will also be undertaken to evaluate the transmission intensity of the disease in the study\nclusters. Costs and cost-effectiveness will be evaluated. Among a random subsample of participants, microfilaria\nprevalence will be assessed longitudinally. A nested process evaluation, using semi-structured interviews, focus group\ndiscussions and a stakeholder analysis, will investigate the community acceptability, feasibility and scale-up of each\ndelivery system.","data_kind":"sample survey data[ssd]"},"production_statement":{"copyright":"Noguchi Memorial Institute for Medical Research"},"method":{"data_collection":{"coll_mode":["Household-level questionnaire"]}},"data_access":{"dataset_use":{"contact":[{"name":"Dziedzom K. de Souza","affiliation":"Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana","uri":"www.noguchi.ug.edu.gh","email":"DdeSouza@noguchi.ug.edu.gh"}]}},"distribution_statement":{"contact":[{"name":"Dziedzom K. de Souza","affiliation":"Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana","email":"balogonia@noguchi.ug.edu.gh"}]},"title_statement":{"title":"Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial","idno":"NMIMR_LYPHATIC_FILARIASIS_2007"},"version_statement":{"version":"v1"},"authoring_entity":[{"name":"Dziedzom K. de Souza","affiliation":"epartment of Parasitology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon-Accra, Ghana"}]}}